Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
